
==== Front
Cell Transplant
Cell Transplant
CLL
spcll
Cell Transplantation
0963-6897
1555-3892
SAGE Publications Sage CA: Los Angeles, CA

39305020
10.1177/09636897241276733
10.1177_09636897241276733
Review
Novel Strategies for Spatiotemporal and Controlled BMP-2 Delivery in Bone Tissue Engineering
Qi Jingqi 12
Wu Hongwei 3
https://orcid.org/0009-0000-5261-1952
Liu Gengyan 1
1 Department of Orthopedics, Third Xiangya Hospital of Central South University, Changsha, China
2 Department of Bioengineering, University of Washington, Seattle, WA, USA
3 Department of Orthopedics, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China
Gengyan Liu, Department of Orthopedics, Third Xiangya Hospital of Central South University, Changsha 410013, China. Email: liugengyan1982@163.com
Hongwei Wu, Department of Orthopedics, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China. Email: hongweiwu@zju.edu.cn
20 9 2024
Jan-Dec 2024
33 0963689724127673323 4 2024
22 7 2024
26 7 2024
© The Author(s) 2024
2024
SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Bone morphogenetic protein-2 (BMP-2) has been commercially approved by the Food and Drug Administration for use in bone defects and diseases. BMP-2 promotes osteogenic differentiation of mesenchymal stem cells. In bone tissue engineering, BMP-2 incorporated into scaffolds can be used for stimulating bone regeneration in organoid construction, drug testing platforms, and bone transplants. However, the high dosage and uncontrollable release rate of BMP-2 challenge its clinical application, mainly due to the short circulation half-life of BMP-2, microbial contamination in bone extracellular matrix hydrogel, and the delivery method. Moreover, in clinical translation, the requirement of high doses of BMP-2 for efficacy poses challenges in cost and safety. Based on these, novel strategies should ensure that BMP-2 is delivered precisely to the desired location within the body, regulating the timing of BMP-2 release to coincide with the bone healing process, as well as release BMP-2 in a controlled manner to optimize its therapeutic effect and minimize side effects. This review highlights improvements in bone tissue engineering applying spatiotemporal and controlled BMP-2 delivery, including molecular engineering, biomaterial modification, and synergistic therapy, aiming to provide references for future research and clinical trials.

Graphical Abstract

BMP-2
gene therapy
biomaterials
bone regeneration
spatiotemporal delivery
cover-dateJanuary-December 2024
typesetterts1
==== Body
pmcIntroduction

Bone morphological protein (BMP), a cytokine of the transforming growth factor β (TGF-β) superfamily, possesses great potential to induce bone repair and regeneration. BMP has about 40 subagents that have different functions. Among them, the application of BMP-2 in clinical trials has been approved by the Food and Drug Administration (FDA) 1 . BMP-2 has been widely used in bone treatments in clinical trials, including repair of femoral head necrosis, lumbar fusion, and acute tibial fractures2,3. The function of BMP-2 is mediated by type I BMP receptor (BMPR-1), type II BMP receptors (BMPR-2), and their downstream molecules Smad1, 5, and 8 (Fig. 1) 4 . Phosphorylated Smad1, 5, and 8 proteins form complexes with Smad4, and then be transported into the nucleus to interact with BMP-2 related transcription factors, including Runt-related transcription factor 2 (Runx2) in osteoblasts 5 . During the early healing phase, BMP recruits mesenchymal stem cells (MSCs) to promote the differentiation into chondroblasts and osteoblasts. Then, continuous chondrogenesis results in a soft callus that temporarily stabilizes the fracture and promotes endochondral bone formation.

Figure 1. BMP signaling pathway.

Although BMP-2 has remarkable effects on osteogenesis, the application has several challenges including short circulation half-life and overdosage use. First, BMP-2 has rapid in vivo clearance because its short half-life is only 7–16 min in the physiological environment 6 . Second, the FDA-approved concentration of 1.5 mg/ml for human use was based on non-human primates (0.75–2.0 mg/ml), which may be overdosage 7 . The overdosage use of BMP-2 causes various side effects such as ectopic bone formation, tissue swelling, postoperative inflammation, osteoclast-mediated bone resorption, and improper adipogenesis1,8. For example, off-label use of recombinant human BMP-2 in posterior interbody fusion resulted in nerve root compression and postoperative radiculitis 9 . Ectopic bone formation and bone cysts in neuroforaminal and soft tissues have been observed after lumbar fusion with BMP-2 10 . Moreover, overdosage BMP-2 can induce cancers. The 40 mg or more dose of BMP-2 in anterior cervical fusion surgery was found to highly correlate with the occurrence of cancer11,12. To conclude, the short circulation half-life and overdosage use of BMP-2 need to be addressed for clinical application.

In bone tissue engineering (BTE), combining interdisciplinary knowledge of stem cell biology, biomaterials, drug delivery, and molecular engineering, has shown great potential for spatiotemporal and controlled BMP-2 delivery. First, BMP-2 activates various important signaling pathways for osteogenesis, cell survival, and apoptosis 13 . Thus, the BMP-2 signaling pathway can be manipulated to enhance its effectiveness, which involves designing biomaterials and gene therapy, to control how BMP-2 is delivered and activated in vivo. Moreover, the activation of BMP-2 should be stabilized to ensure BMP-2 remains active and effective for a long period, avoiding rapid degradation or inactivation. Finally, stabilizing the BMP-2 activity can more effectively promote the formation of new bone tissue, which is particularly beneficial in treatments involving bone fractures, spinal fusions, and other orthopedic procedures 13 . As for the modification, the BMP-2 protein and its activators and inhibitors can be targeted by molecular engineering. Second, BMP-2 can not only affect the proliferation and differentiation of progenitor cells but also show synergistic effects with other growth factors. Therefore, combining BMP-2 with different growth factors can strengthen the osteoinductive capability of BMP-2 on stem cells. Third, regulating the chemical and physical properties of extracellular scaffolds can reduce the burst release and supraphysiological levels of BMP in the microenvironment 14 . For instance, the polyetheretherketone cages and absorbable collagen sponge have been applied to block the exposure of BMP-2 to surrounding tissues, showing reduced side effects 15 . Additionally, the demineralized bone matrix around the BMP-2 sponge has been reported to reduce the complications compared to the use of the BMP-2 directly 12 . Above all, the dosage and localization of BMP-2 are closely related to the treatment results and complications. Here, cutting-edge BTE strategies to achieve spatiotemporally controlled release of BMP-2 have been discussed, aiming to provide a reference for bone repair and regeneration.

Bone Diseases and Regenerative Proposals

Bone occupies approximately 15% of human body weight. As a highly metabolic active connective tissue, bone has the capability of resorption and remodeling 16 . However, large bone defects, defined as more than 2.50 cm in critical size, cannot be healed fully and require regenerative and reconstruction treatment 17 . For example, trauma, congenital anomalies, age-related diseases, and musculoskeletal tumors are common pathotypes 18 . Nowadays, bone disease incidence is increasing mainly because of the sedentary lifestyle and rising average age 19 , which has become a significant socio-health problem.

BTE is an interdisciplinary strategy that manipulates biomaterial scaffolds, biochemical factors, and cells in vitro to make a graft for implantation. First, biomaterial scaffolds with porous microstructure possess high biocompatibility, mechanical properties, and biodegradability20,21. Thus, the scaffolds can mimic the extracellular matrix, providing a regenerative microenvironment for osteogenesis, vascularization, and nutrient transportation. Second, osteoinductive growth factors including BMP-2 regulate cell metabolism to promote the growth of bone and blood vessels20,22. The controlled delivery of growth factors in scaffolds can enhance progenitor cell proliferation, differentiation, and migration both in vitro and in vivo. Third, the BMP-2 protein and its signaling pathway can be modified to increase the stability and metabolism of BMP-2 in the process of bone regeneration. Overall, current trends of BTE are reducing morbidity on the donor site, enhancing the geometric compatibility of the graft with the recipient site, and addressing constraints on graft volume. Various BTE research explored the effects of protein modification, molecular engineering, and delivery system optimization on the BMP-2 delivery, to enhance the therapeutic effects of bone diseases. To conclude, the development of novel strategies for the spatiotemporal and controlled delivery of BMP-2 in BTE aims to improve the efficiency and safety of BMP-2 therapy. By leveraging advanced materials, nanotechnology, and innovative delivery methods, researchers hope to enhance the healing process and achieve better clinical outcomes of bone healing and regeneration.

BMP-2 Delivery System

The physiochemical and biological properties of BMP-2 motivate the need to design scaffolds that maintain BMP-2 bioactivity and enhance its retention at implant sites. The delivery system mainly includes binding and non-covalent binding 23 . First, the covalent binding of BMP-2 protein to scaffolds by coupling amine functional groups can enhance cell adhesion and differentiation in culture substrates 24 . However, this method is time-intensive and cost-intensive. Due to the difficulty in controlling the modification site, the active site of the BMP-2 may be obstructed, hindering the biological activity 25 . Second, the non-covalent incorporation of BMP-2 into scaffolds contains electrostatic interactions, hydrophobic interactions, hydrogen bonding, and Van der Waals forces 26 . The disadvantage is that it may cause an initial uncontrolled burst release, resulting in super-physiological levels of growth factor in the microenvironment and systemic abnormalities such as ectopia bone formation, osteoclast-mediated bone resorption, mineral deposition in muscle tissue, and inappropriate lipogenesis27,28. To address these problems, pretreatment with biomaterials and pharmacological agents to control the time and speed of the release of BMP-2 can improve the results of bone regeneration and repair.

Three-Dimensional (3D) Bioprinting

Three-dimensional (3D) bioprinting promoted the development of BTE by enabling the free-form fabrication of cell-laden hydrogel scaffolds with controllable features and interconnected pores. This technique uses biomaterials to produce elaborate 3D structures with specific shapes and features for clinical implantation 29 , showing great potential in the delivery of BMP-2.

Hydrogels are good candidates for bio-ink due to good biocompatibility and plasticity30,31. For example, alginate is a natural biopolymer. In the presence of divalent cations such as calcium, alginate is easily cross-linked by ions to form stable hydrogels 32 . Although alginate bio-inks lack the ability of bone conductivity and bone inductance, BMP-2 incorporation can enhance bioactivity. A novel bio-ink using BMP-2-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles and alginate has been formulated 33 , showing enhanced mechanical properties and printability. Moreover, 30 mg/ml PLGA nanoparticles and 3% w/v alginate were suitable parameters for 3D bioprinting concerning printability and stability. BMP-2-loaded PLGA nanoparticles displayed sustained release in vitro for up to two weeks. As for the osteogenesis efficiency, the nanoparticles showed enhanced calcium deposition, alkaline phosphatase activity, and gene expression of osteogenic markers in MSCs. Additionally, a projection stereolithographically fabricated hydrogel scaffold has been bio-printed to encapsulate BMP-2-engineered human MSCs 34 . MSCs showed sustained expression of BMP-2 and differentiation into osteogenic lineages, without extra BMP-2 supplementation. As for in vivo evaluation, an intramuscular implantation model was utilized in severe combined immunodeficiency mice. Results revealed rapid bone formation, and mature trabecular bone structures accompanied by substantial vascularization 14 days after implantation. In a word, these findings highlight the applications of 3D bioprinting for the customized treatment of bone defects.

Scaffold Modification

In BTE, scaffolds play a crucial role by providing a 3D environment that mimics the extracellular matrix to recruit and direct osteogenic cells. The biocompatibility and biochemical properties of scaffolds significantly influence cell survival, infiltration, and osteogenesis. Various biomaterials can be utilized to incorporate BMP-2 into the scaffold, including natural polymers, synthetic polymers, bioceramics, and nanomaterials. To achieve spatiotemporally controlled release of BMP-2, variable modifications have been considered to improve the mechanical strength, osteoconductive capacity, and osteoinductive capacity of the biomaterials, such as mineralization, chemical functionalization, surface modification, and covalent functionalization via various linkers 35 .

Natural polymers

Inspired by the composition of the extracellular matrix, collagen was one of the first natural polymers applied for BMPs delivery. It has been considered as the gold standard carrier for BMPs approved by FDA to treat long bone fractures, spinal fusion and periodontal regeneration 36 . Currently, novel natural polymers have been characterized and detected in the application of BMP-2 delivery in BTE.

Recent studies reported that Heparin, a common glycosaminoglycan, is a natural polymer that can form a reversible combination by electrostatic interaction to adsorb positively charged BMP-2 37 . Heparin has a dual effect on the osteogenic activity of BMP-2. A low concentration of heparin was effective on bone regeneration, but a high concentration of heparin showed inhibiting effects 38 . Prolonged culture with heparin can stimulate BMP-2-induced osteogenesis via the downregulation of BMP-2 antagonists and inhibitory regulator Smads 39 . As for BMP-2 delivery, the heparin chains have been added into fibrin 40 , collagen 41 , alginate 42 , and PLGA scaffolds 43 . However, the noncovalent adsorption of heparin onto collagen sponge scaffolds did not enhance BMP-2–mediated bone repair in vivo 41 . Therefore, covalent heparin immobilization strategies, including 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide coupling and photo-cross-linking were used 44 . While these strategies have improved BMP-2–mediated bone formation in vivo, the dose dependency of heparin adding to scaffold on bone formation did not be detected. Based on these, heparin has been modified with methacrylamide and turned into heparin microparticles (HMPs) to adsorb BMP-2 37 . The results showed that HMPs had a strong effect on BMP-2 adsorption and sustained release. Every 0.8 mg HMP can absorb 1 mg BMP-2. Later, BMP-2-loaded HMPs with arginine-glycine-aspartic acid-activated alginate hydrogels were generated to cure the 8-mm femur bone defect. The patients showed successful union without obvious ectopic bone formation 45 . However, heparin is an anticoagulant drug in clinical use and may cause uncontrolled bleeding and even death. Currently, the side effects of heparin microspheres on hematoma require further research, which is an unavoidable problem in clinical applications. Taken together, heparin increases BMP-2 retention in vivo, improves the spatial localization of bone formation in large bone defects, and reduces heterotopic ossification. Further study should balance the strong affinity interactions between heparin and BMP-2 to improve BMP-2 delivery.

Alginate is a polysaccharide derived from algae, which is widely used as a natural polymer for cell encapsulation in tissue engineering 46 . Alginate possesses favorable properties with cytocompatibility, adhesion, and degradability. In addition, alginate can absorb positively charged BMP-2 through electrostatic force, and then release it gradually. Alginate microbeads have demonstrated their effectiveness as carriers for BMP-2, significantly increasing ALP activity in mesenchymal stem cells in vitro over 14 days, and promoting bone formation in both ectopic and calvarial defect sites in animal models 47 . Alginate has been modified with γ-ray irradiation 48 , but about 98% of BMP was released within the first week. Additionally, the alginate has been oxidated but failed to have sustained release of BMP-2 49 . Later, BMP-2 was encapsulated with alginate in microspheres, and the rats with 5-mm skull defects recovered in 2 months 47 . Although BMP-2 was released 70% to 80% in 7 days, the loading capability was greater than in the previous two experiments. To improve the retention of BMP-2, alginate can work with other biomaterials, such as collagen 50 , calcium-based cement 51 , nano-silica 52 , nano-hydroxyapatite 53 , saponite 54 , and polycaprolactone scaffold 55 . Recently, optimization of the BMP-2-alginate delivery system has been reported. Due to poor interaction between BMP-2 and alginate, BMP-2 embedded in alginate saline gel is prone to rapid diffusion and cannot maintain long-term activity 56 . It has been reported that a mixture of alginate and heparin hydrogels could bind to BMP-2 45 . Furthermore, alginate has been chemically sulfated to produce alginate sulfate, a structural and functional mimic of heparin which can strongly interact with BMP-2 57 . As a result, the modified scaffold maintained the long-term activity of BMP-2 for BTE. The proliferation and phenotypic maintenance of bovine chondrocytes were significantly improved in hydrogels containing alginate sulfate compared to alginate saline gel controls 58 . In conclusion, alginate can be utilized as an effective BMP-2 delivery vehicle in BTE.

Chitosan is a biocompatible and biodegradable polysaccharide derived from chitin, which has been considered a good candidate for bone grafts 59 . The presence of amino and hydroxyl groups of chitosan improves the absorption ability of many materials such as drugs, ions, and growth factors 60 . These groups are also modifiable positions to link extra functional groups to further enhance the covalent adsorption. For example, chitosan has been modified with methacrylate, thus, it can be transformed into hydrogel under the reaction of visible light. The methacrylate-modified chitosan was applied to deliver BMP-2 61 . Results showed that about 30% of BMP-2 was released on the first day, and 70% in the later week. As a result, the 3-mm defect of the rat tibia could be recovered in 4 weeks, suggesting the potential role of chitosan delivery of BMP-2 in bone repair. Moreover, 2-N,6-O-sulfated chitosan (26SCS) showed an immunomodulatory role in the BMP-2-induced osteogenesis. The modified chitosan induced beneficial immune microenvironments, enhanced the relationship between immune cells and stem cells, and promoted the osteogenic differentiation of stem cells 62 . As for the mechanism, the 26SCS-triggered immune microenvironment promoted the chemotaxis of bone marrow stromal cells through upregulated BMPR-IA expression and amplified BMP-2/Smad signaling. Furthermore, the immune microenvironment had a positive effect on the pro-angiogenic effect of bone marrow-derived mesenchymal stem cells (BMSCs). Therefore, modifications of chitosan are significant for constructing a profitable microenvironment to enhance BMP-2-triggered osteogenesis.

Synthetic polymers

Synthetic polymers have received great attention in the last decades because they can combine various properties of individual polymers, including stability, biocompatibility, and mechanical strength 63 . Compared to natural polymers, synthetic polymers can avoid the potential risks of transferring diseases from animals, immunogenicity, or inflammation. For example, PLGA has good biocompatibility and biodegradation and has been approved by the FDA 64 . PLGA possesses great potential to deliver BMP-2 in BTE. For example, BMP-2 can be absorbed in the pores between PLGA and polyelectrolyte multilayer fabricated by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysulfosuccinimide reaction 65 . Results showed that the PLGA/PEG scaffold loading BMP-2 reduced the hematoma complication compared to the direct use of BMP-2. Besides, PLGA-multistage vector composite microspheres (PLGA-MSV) were applied to transport BMP-2, showing enhanced osteoinduction in BMSCs in rats 66 . However, the manufacturing operation of the PLGA-MSV may be toxic in vivo due to the toxic solution. To overcome this limitation, the electrospinning technique provides a safe opportunity to produce PLGA nanofibers. For instance, electrospinning can be used to combine PLGA nanofibers with BMP-2, achieving the sustainable release of BMP-2. However, the osteoinduction level in vivo needs to be further verified 67 . Besides, high voltage during electrospinning could damage the BMP-2 and PLGA scaffold and then decrease the absorption dosage of BMP-2. These results suggested that PLGA can be applied to construct BMP-2-loaded composite scaffolds that had the potential to be used as a bone implant, as osteogenic ability was promoted by the prolonged release of BMP-2.

Bioceramics

The carrier of BMP-2 with calcium-phosphate-based materials was inspired by the natural system of bone. Hydroxyapatite occupies around 70% mineral component of teeth and bones and has been widely used as bone scaffolds, implant coatings, and drug delivery in bone regeneration 68 . Because of its osteoconductive capacity, and physicochemical and biological properties, hydroxyapatite induces the migration of host bone-forming cells into porous scaffolds, enhancing the osteogenesis process63,69. In the application of BMP-2 delivery, the micro- or nanostructure of hydroxyapatite has shown improved performance in delivering BMP-2. For instance, 100-µm nanostructured microspheres have been applied in controlled novel delivery of rhBMP-2, which showed significantly enhanced capacity to reconstitute radial bone defects in rabbits and quick and complete new bone formation within 12 weeks compared to hollow hydroxyapatite microspheres without BMP-2 or soluble BMP-2 without a carrier 70 . Thus, the hollow hydroxyapatite microspheres could be a potential carrier for BMP-2.

Besides hydroxyapatite, mesoporous bioactive glass (MBG) possesses promising biocompatibility, osteo-conductivity, osteo-inductivity, osteogenesis, biodegradability, and excellent mechanical strength, which are essential to be selected as bone substitutes 71 . Due to the structure, MBG can mimic the native bone pore size and interconnectivity to promote bone regeneration. Besides, it is a good candidate to deliver drugs or growth factors 72 . The carboxyl bond of BMP-2 has been connected to the amine bond of MBG nanoparticles through 1-ethyl-3-(-3-dimethyl aminopropyl) carbodiimide hydrochloride-N-hydroxy succinimide reaction 73 . In vitro, MBG was found to be cytocompatible and induce a pro-osteogenic response in primary human MSCs. In preclinical rodent models, BMP-2-loaded MBG significantly enhanced bone formation and microarchitecture of bone. The release of BMP-2 in MBG was about 70% within 1 month, which could recover a 5-mm skull defect. Lin et al. immobilized BMP-2 on the MBG scaffold surface via electrostatic interaction 74 . Although 25% of BMP-2 was released in 7 days, MBG-loaded BMP-2 still showed great regeneration in 16-mm bone defect in rabbits. In a word, the application of MBG is limited by the low encapsulation efficiency of BMP-2 and the burst release. Additionally, the harmful solvents used in scaffold fabrication can influence the bioactivity of BMP-2 and threaten the health of patients. MBGs produced by an aerosol-assisted spray-drying scalable process showed prolonged release of low-dose BMP-2 without affecting material properties 75 . The use of MBG as a biocompatible carrier for localized and sustained low-dose BMP-2 release could limit BMP-2-derived side effects, allowing for the safe use of BMP-2.

Nanomaterials

Nanomaterials possess high surface area, tunable size, and functionalization capabilities, making them ideal candidates for delivering BMP-2 in a controlled and efficient manner. For instance, carbon quantum dots (CDs) with ultra-small sizes are emerging stars in drug delivery because of their biocompatibility, high water dispersibility, and remarkable photoluminescence properties76,77. CDs can be conjugated with drugs through surface modification78,79. Based on these, BMP-2-conjugated CDs (BMP-2-CDs) can be used for bioimaging and tracking of growth factor delivery that can meet the requirements of therapeutic applications. Besides, sustained release and long persistence of BMP-2 undergoing the treatment are important to prevent side effects 80 . A composite scaffold containing pectin particles loaded with BMP-2-CDs has been constructed for BMP-2-CDs release systems 77 . Using the microfluidic method, BMP-2-CDs were encapsulated in pectin particles with narrow particle distribution and then loaded into a composite scaffold composed of gelatin, elastin, and hyaluronic acid. BMP-2-CDs were continuously released from the composite scaffold for 21 days, showing high controllable drug release ability. In vitro tests of MG-63 cells demonstrated its biological properties of intercellular absorption and enhancement of BMP-2-CDs and their bone-promoting effects. This platform showed great potential in bone tissue regeneration by utilizing pectin particles carrying BMP-2-CDs as a growth factor delivery biological imaging agent and adjusting the composition of scaffolds.

Codelivery of BMP-2 with Other Growth Factors

Bone regeneration is under the control of the interaction of osteoblast-derived bone formation and osteoclast-derived bone resorption, which can be regulated by various growth factors. BMP-2 possesses synergistic effects with other growth factors, including antiadipogenic, anti-inflammatory, pro-vascularization, and osteogenesis. Thus, an appropriate combination of growth factors is significant to improve the orthopedic surgeon for osteo-angiogenesis.

Vascular Endothelial Growth Factor

Vascular endothelial growth factor (VEGF), one of the strongest angiogenic factors, regulates the proliferation and migration of endothelial cells to promote angiogenesis. VEGF also involves in osteogenesis by influencing osteoblast differentiation and cartilage absorption 81 . Therefore, the combination of VEGF and BMP-2 can promote vessel invasion and blood supply to facilitate new bone formation. In the process of osteogenesis, osteoblasts produce VEGF, stimulating osteogenesis and inhibiting lipogenesis through Runx2 and PPARY2 82 (Fig. 2). Meanwhile, VEGF can activate the Akt/β-catenin signaling pathway, rising BMP-2 levels in the vascular-associated MSCs 83 . As a result, the increased BMP-2 mediated by osteoblasts stimulates osteoblast differentiation as well as VEGF production in a positive feedback loop 84 . Therefore, angiogenesis and bone regeneration are closely coupled, which can mutually promote osteogenesis (Fig. 3).

Figure 2. Strategies for BMP-2 gene therapy in bone treatment.

Figure 3. Various and complex combinations of bioactive factors with delivery systems for bone tissue engineering applications being developed recently.

As for applications, the joint treatment of VEGF and BMP-2 effectively promoted the osteogenic induction of mouse osteoblasts mainly through the activation of the p38 mitogen-activated protein kinase (MAPK) pathway to enhance the nuclear translocation of osterix protein 85 . Consistent with this study, the combination therapy in rabbit mandibular bone defect also showed enhanced osteogenesis and angiogenesis than those therapies that used BMP-2 alone 86 . To achieve the controlled release of BMP-2 and VEGF, polydopamine coating was applied to load the BMP-2 and VEGF easily and safely. The polydopamine possesses high hydrophilicity and bioactive functional groups to facilitate cell attachment and expansion on the surface of materials 87 . In vitro experiments showed high osteogenesis expression of runt-related transcription factor 2, osteopontin, and alkaline phosphatase induced by BMP-2 immobilized on nanofibers 88 . Similarly, VEGF sustained release showed angiogenic differentiation of BMSCs with the increased angiogenesis expression of fetal liver kinase-1 and vascular endothelial cadherin 88 . Moreover, using an electrospinning poly-l-lactic acid (PLLA) nanofiber with the VEGF-BMP-2 polydopamine coating, the artificial periosteum accelerated the osteogenesis and angiogenesis in rat femoral defects along with a massive periosteum defect 88 . Additionally, VEGF and BMP-2 possess short half-lives, VEGF is approximately 13 min, and BMP-2 is 7–16 min. To solve this problem, BMSCs were engineered with chemically modified mRNAs encoding the hBMP-2 and VEGF-A genes, which showed great potential to therapeutically heal bone 89 . In this study, a cell-based technology system was applied to enhance mRNA delivery and subsequent in vivo–produced protein 90 , which could circumvent issues related to Lipid Nanoparticles (LNP) cytotoxicity. Moreover, the modified RNA is a non-integrating, non-viral, mRNA approach that gained substantial merit over gene-based therapies91,92. The results showed increased expression of osteogenic-related markers and mineralization deposits. Moreover, the modified BMSCs incorporated with a collagen scaffold could accelerate osteogenesis through the simultaneous stimulation of angiogenesis in an in vivo rat calvarial defect model. In general, the synergistic effect of VEGF with BMP-2 shows a promising result under the proper control of the dosage and time of growth factors.

Basic Fibroblast Growth Factor

Similar to VEGF, basic fibroblast growth factor (bFGF) is an angiogenic growth factor that promotes the migration and proliferation of various cells including vascular cells and osteoblasts. In the early stage of wound healing, angiogenesis is necessary for the transport of MSCs and the supply of oxygen and nutrients 93 . Combined treatment with BMP-2 and bFGF has been reported to synergistically enhance bone regeneration compared with using BMP-2 or bFGF alone 94 . For example, a composite nanofiber scaffold composed of poly(l-lactic-co-glycolic acid), hydroxyapatite, and graphene oxide has been fabricated to deliver bFGF and BMP-2 simultaneously. The result showed that bFGF and BMP-2 loaded in the composite nanofiber scaffolds have a synergistic differentiation effect on the cell adhesion, proliferation, and osteogenesis differentiation of MC3T3-E1 cells. More importantly, the release kinetics and doses are vital to determine the synergistic effect of BMP-2 and bFGF. A low dose of bFGF combined with a high dose of BMP-2 has been found to enhance bone formation, while a high dose of bFGF combined with a low dose of BMP-2 impeded the process 95 . Moreover, a study using rat models with femoral condyle defects showed that the rapid release of bFGF combined with the sustained release of BMP-2 caused an inhibitory effect on osteogenesis 86 . The reason mainly lies in the high-dose bFGF-induced BMP-2 inhibition signaling Smad-6, enhancing osteoclast formation, and finally, the bone density was decreased 96 . In addition to the dose effect, the release kinetics of growth factors can influence the process of osteogenesis. bFGF has mitotic activity and can reduce the expression of osteoblastic markers in less mature cells 95 . Rapid release of bFGF may reduce the osteogenic potential of osteoprogenitor cells, thus delaying bone regeneration. Therefore, exploring a standard application of the relative doses and release kinetics of BMP-2 and bFGF is significant to achieve a greater synergistic effect on bone healing. For instance, bFGF can be released more intelligently at the early stage of wound healing, and BMP-2 can be released later to enhance the osteogenic differentiation of stem cells to promote bone regeneration. In general, bFGF combined with BMP-2 has a wide application prospect in bone regeneration.

NELL-1

Neural EGFL-Like 1 (NELL-1) is an osteoinductive cytokine that can induce bone and cartilage regeneration. Additionally, NELL-1 inhibits osteoclast metabolism and adipogenesis process 97 . As for applications, NELL-1 has been used to induce bone healing of femoral segments and skull defects in rats and promote lumbar fusion in rats, sheep, and non-human primates 98 . Based on these, the synergistic effect of NELL-1 and BMP-2 has great potential to enhance the osteogenic response and significantly reduce the side effects of BMP-2 99 . First, through regulating the lipid metabolism, NELL-1 is antiadipogenic which can deal with the BMP-2-induced adipose tissue, thus improving the quality of regenerated bone99–101. Second, NELL-1 is anti-inflammatory by inhibiting the immune response induced by BMP-2 because of the single nucleotide polymorphisms in the NELL-1 gene 99 . Third, NELL-1 can also stimulate the generation of blood vessels in the early stage of bone healing and strengthen the migration of MSC 102 . In the rat spinal posterolateral fusion experiments, low doses of BMP-2 and NELL-1 synergy in the osteogenesis of MSC differentiation showed great mineralization with negligible heterotopic bone and adipose tissue 103 . However, in vivo research showed that NELL-1 failed to enhance osteoblastic differentiation of BMSCs or induce spinal fusion because the ability of NELL-1 to promote osteogenesis and suppress adipogenesis needs Wnt signaling 104 . Moreover, the short half-life of NELL-1 in vivo may limit its clinical use in systemic therapy. To overcome these shortcomings, structural modifications such as PEGylation have been used to improve the pharmacokinetics of NELL-1 to prolong its circulation time in vivo 105 . In conclusion, NELL-1 can enhance BMP-2-induced osteogenesis which is prospective to be translated into clinical.

NGF

Nerve growth factor (NGF) promotes osteoblast mitosis, skeletal formation, and bone ossification via BMP-2/Smad signaling. NGF can be widely found in skeletal components, including bone marrow mesenchymal stem cells, regional callus tissue, osteoclasts, osteocytes, chondrocytes, and synovial fibroblasts 106 . Local administration of NGF enhanced bone cell metabolism and osteogenic capacity, and promoted the synthesis of VEGF during the healing of fractures 107 . Exogenous NGF could facilitate innervation and angiogenesis, ultimately improving the mechanical properties of bones 108 . Furthermore, high expression of NGF and its high-affinity receptor P140TrkA has been observed in human osteoarthritic cartilage, where they stimulate chondrocyte metabolism, cartilage matrix formation, and collagenase production 109 . Notably, NGF effectively reduces inflammatory reactions during the healing of fractures. Consequently, applying NGF in BMP-2-driven BTE holds significant importance.

BMP-2 Signaling Pathway Modification

In BTE, modifying the BMP-2 signaling pathway represents great potential to enhance bone regeneration. BMP-2 is a key growth factor that regulates osteoblast differentiation and bone formation. By altering its signaling pathway, the BMP-2 activity can be stabilized to improve outcomes in bone repair and regeneration. Techniques for modifying the BMP-2 pathway include protein engineering of BMP-2 and applying gene therapy or small molecules to affect BMP-2 receptor interactions and downstream signaling cascades. These modifications can enhance BMP-2 effectiveness in stimulating osteogenesis and angiogenesis. Advances in this area hold promise for developing effective bone grafts, implants, and other therapeutic strategies for bone defects and injuries (Table 1).

Table 1. The Example, Pros, and Cons of In Vivo and Ex Vivo Gene Delivery, Viral and Non-Viral Vectors.

Method	Example	Advantages	Disadvantages	
In vivo gene delivery	1. Vector;
2. Gene-activated matrix	Straightforward	1. Difficult to target specific cells or tissues;
2. Risk of unwanted distribution;
3. Less control over the efficiency of expression	
Ex vivo gene delivery	Ex vivo modified cells	Greater control of targeted cells and expression level	1. Complex protocols of cell isolation and expansion;
2. costly product	
Viral vectors	1. Adeno-associated virus;
2. Adenovirus;
3. Retrovirus;
4. Lentivirus	High efficiency of gene delivery	1. Risk of an immune response;
2. Risk of tumorigenicity due to insertional mutagenesis;
3. Stable integration might lead to an excess of protein secretion;
4. Production might be costly and complex	
Non-viral vectors	1. Nanoparticles;
2. Electroporation;
3. Chemicals	1. Safer compared to viral vectors;
2. Simpler production process;
3. Easier manipulation	Low efficiency of gene delivery	

Protein Modification of BMP-2

Currently, BMP-2-driven BTE is widely used in clinical trials, but it is concerned with dosage efficacy and short circulation half-life. To solve these problems, protein modification has the potential to realize site-specific covalent immobilization of BMP-2 to scaffolds. The BMP-2 can be infused with a second protein which has been utilized in enzyme immobilization. For example, T4 lysozyme, a soluble and small enzyme, functions as an inert protein spacer to attach to the carriers to enhance the rescued activity of target proteins110,111. Based on these, polyhistidine tag-T4 Lysozyme was genetically fused at the N-terminus of BMP-2 and used as a protein spacer to enhance the BMP-2 stability and solubility 112 . Additionally, the fused protein could mediate the site-specific covalent anchoring of BMP-2 upon binding to nickel-chelated nitrilotriacetic acid microparticles 112 . As for the mechanism of BMP-2 modification, the modified BMP-2 featured an N-terminal His6 tag as a location for the targeted covalent integration of BMP-2 onto the solid carrier. Moreover, the T4L domain played a role in improving solubility and stability. This domain also created a separation between BMP-2 and the scaffold, thereby promoting its bioactivity. Meanwhile, the C-terminal BMP-2 domain contributed to the osteogenic activity. In the future, the positions of domains can be applied for BMP-2 engineering. For example, the T4 Lysozyme domain can be placed at the C-terminus of BMP-2. Additionally, the length and composition of the protein linkers need to be further explored for an optimal active BMP-2 construct.

Besides protein modification, the metabolism of BMP-2 can be improved. BMP-2 shows rapid metabolic adaption including glycolysis and oxidative phosphorylation. Bone remodeling is a biosynthesis process that requires a large amount of energy 113 . Therefore, the energy metabolism of BMP-2 may affect the bone repair and regeneration of BTE. The inadequate activation of the metabolic state may cause the ineffectiveness of low-dose BMP-2. Magnesium, a main component of bone, is critical to balance the metabolism and biomineralization in osteogenesis 114 . In cellular physiology, magnesium regulates the protein and ATP synthesis of mitochondria directly 115 . Inspired by the dual functions of magnesium, a magnesium-based bioenergetic-driven system was developed to improve low-dose BMP-2-driven regeneration 33 . In this system, magnesium upregulated the expression and activity of metabolic enzymes and the glycolysis and oxidative phosphorylation signaling pathways. Through enhancing the metabolism level, the osteo-inductivity of BMP-2 can be increased to fuel osteogenesis.

Molecular-Engineered BMP-2 Signaling Pathway

BMP-2 is involved in many important signaling pathways for osteogenesis, cell survival, and apoptosis, thus, BMP-2 signaling cascades can be regulated by various proteins 116 . In nature, BMP-2 induces the differentiation of stem cells into osteogenic lineage by interacting with surface receptors, activating subsequent signaling pathways, and increasing the expression of osteogenic genes (Fig. 1).

BMP-2 is regulated by several secreted antagonists intracellularly and extracellularly, such as noggin, sclerostin, and follistatin. The antagonists bind to BMP-2 and hinder its attachment to surface receptors, thereby reducing the activity of BMP-2 and impeding the osteogenic differentiation of osteoprogenitor cells 117 . In BTE, BMP-2 antagonists can be repressed to increase the activity of BMP-2, reducing the dosage use of BMP-2. When osteoprogenitor cells are stimulated by BMP-2, they produce a BMP antagonist Noggin 118 . The Noggin driven negative feedback loop may elucidate the need for higher-than-normal doses of BMP-2 to address bone defects in clinical applications. Based on this mechanism, a study co-delivered the BMP-2 gene and CRISPR interference (CRISPRi) targeting Nog into adipose-derived stem cells (ASCs) by hybrid baculovirus (BV) system 119 . This system showed prolonged BMP-2 expression upregulated the Noggin level as well as the CRISPRi suppressed the expression of Noggin for at least 14 days. The result showed enhanced osteogenesis in ASCs and calvarial bone healing in CRISPRi-engineered ASC-implanted rats. Therefore, Noggin inhibition alleviated its antagonistic effects on BMP-2 and enhanced BMP2-induced osteogenesis. Here, the CRISPRi system is introduced by baculovirus which effectively transports large genetic payloads into stem cells with high safety 120 . BV can accommodate genetic cargoes of at least 38 kb and transduce ASC and BMSCs with efficiencies exceeding 95%121,122. Concerning safety, the BV genome does not integrate into the host chromosome and naturally degrades over time 121 . For example, a Cre/loxP-based hybrid baculovirus vector facilitates the formation of DNA minicircles in over 90% of ASC123,124. These minicircles exist as extrachromosomal episomes and eventually degrade. To conclude, the hybrid BV has great potential to engineer the BMP-2 signaling pathway in BTE because of its high trans-genetic efficiency and biocompatibility.

Besides noggin, Casein Kinase 2 (CK2), a key inhibitor of the BMP-2 signaling pathway, has been modified to increase the activity of BMP-2. CK2 binds to the phosphorylation sites of BMPRIa to inhibit the BMP-2-triggered downstream activation of the Smad pathway or non-Smad pathway 1 . Based on this, the deletion of BMPRIa gene showed enhanced osteogenesis in mice 125 . Referring to the three phosphorylation sites of BMPRIa, three peptides were designed to bind and prevent the interaction between CK2 with BMPRIa. The results showed increased osteogenesis, and chondrogenesis which is similar to the experiments of BMPRIa mutants 126 . Additionally, a BMPRIa mutant lacking a serine to prevent the binding of CK2 was overexpressed, showing increased mineralization 127 . All of these indicate that the presence of CK2 inhibitors may activate the BMP-2 signaling pathway. Although increasing researchers have shown different regulatory methods of BMP-2 signaling pathways, the clinical translation of the engineered BMP-2 signaling pathway still needs further exploration.

Discussion

BTE based on bone structure, bone mechanics, and tissue formation aims to induce new functional bone tissues. The compositions of BTE include a biocompatible scaffold mimicking the microenvironment of bone extracellular matrix, osteogenic cells which will proliferate and differentiate into the bone matrix, and growth factors that direct the cells to specific phenotypes. BMP-2, one of the strongest osteogenesis factors, plays a significant role in BTE. BMP-2 recruits progenitor cells on the local site and induce the osteogenic process. However, its side effects are still a concern, including osteolysis 128 , retrograde ejaculation 129 , immune response 130 , and heterotopic bone formation 131 . Most importantly, BMPs may induce cancer 132 . Therefore, appropriate BMP-2 treatment in BTE is urgent to eliminate complex bone graft surgery and long-term healing effects in the clinic.

Among the side effects of BMP-2, the oncogenicity of overdosage BMP-2 has been considered. The BMP antagonist DAN domain BMP antagonist family member 5 (DAND5) has been found to reactivate dormant metastatic breast cancer cells in the lung 133 , and BMP signaling is tumor suppressive in studies overexpressing BMP-2 receptors 134 . These conflicting functions of BMPs in cancer are further complicated by data showing that BMP-2 inhibits tumor cell lines from prostate, ovarian, and breast cancers. Currently, the FDA has ruled out the use of BMP in patients with a history of cancer. Most of the reported complications are related to supraphysiological doses administered clinically 10 . Although initial clinical studies used recombinant human BMP-2 doses in the range of 10–12 mg in the treatment of long bone defects, the optimal dose of BMP-2 was currently considered to be 1–2 μg/kg 135 . The dose can be further minimized if the release and kinetic of BMP-2 can be controlled.

Besides the reduction of the dosage use of BMP-2, novel strategies have been applied to increase the efficiency of BMP-2 by maintaining its bioactivity throughout the healing process. Current delivery systems often face difficulties in preserving the BMP-2 structure and function, leading to potential off-target effects. Efficient BMP-2 delivery requires precise targeting and controlled release, such as the development of smart nanoparticles, injectable hydrogels, or bioresponsive scaffolds. These techniques allow for localized delivery in response to specific biological signals, ensuring that BMP-2 is released exactly where and when it is needed. Future research should focus on developing stabilization techniques that protect BMP-2 from degradation and denaturation.

In BTE, BMP-2 potency can be increased through delivery systems and combination with growth factors. First, the scaffolds can control stable and sustained BMP-2 release through covalent or noncovalent binding. Moreover, the scaffolds should meet the requirement of cell metabolism, proliferation, differentiation, and attachment. Thus, easily fabricated, injectable, and transplantable biomaterials need to be considered as delivery systems of BTE. Various techniques including gene modification and 3D bioprinting have been applied to improve the functions of BMP-2. By engineering physical and chemical properties and microstructure of composite biomaterials, the loading and releasing amount as well as bonding strength of BMP-2 can be improved. For example, collagen–hydroxyapatite composite scaffolds were modified with BMP-2 and loaded with biodegradable microspheres containing encapsulated alendronate 135 . The findings revealed an initial release of BMP-2 over a few days, followed by the sequential release of alendronate after 2 weeks. These composite scaffolds notably enhanced osteogenic activity due to the synergistic effect of BMP-2 and alendronate. Improved bone regeneration was observed 8 weeks after implantation in a rat model with an 8-mm critical-sized defect.

Moreover, understanding the molecular mechanisms of crosstalk pathways can reduce the dosage of BMP for future BTE applications. Therefore, the BMP-2-induced mechanistic cascade needs to be examined. First, various growth factors can regulate the BMP-2 signaling pathway to affect bone healing. That’s mainly because bone healing is a complex process involving cell interactions, extracellular matrix production, mineralization, and vascularization which contains various growth factors as players. Properly combining growth factors with BMP-2 to modulate the BMP-2 signaling pathway has shown great potential to increase the efficiency of bone repair and regeneration. Second, molecular engineering of BMP-2 protein and it signaling pathway show great potential to increase the results the BMP-2 BTE. First, stable half-life protein structure of BMP-2 can be predicted by computational methods including Rosetta, Homology Modeling, and Ab Initio (De Novo) Structure Prediction. After constructing the stable BMP-2 protein, researchers can add them into the microenvironment of scaffold. Then, the activity and degradation of BMP-2 can be tracked. Biocompatibility testing, histological analysis, immunohistochemistry and immunofluorescence and micro-computed tomography can be applied for verification. Second, BMP-2 signaling inhibitors and activators can be targeted to modulate the efficiency of BMP-2 on osteogenesis. Characterizing the chemical and biological properties of the modulators is crucial for further development and potential clinical applications. As for experiments, we can utilize cell lines in responsive to BMP-2 signaling to measure BMP-2-induced responses including phosphorylation of SMAD proteins, gene expression, or alkaline phosphatase activity. Then, researchers can assess the impact of scaffolds containing potential inhibitors and activators on these BMP-2-induced responses. In animal models, the effects of BMP-2 signaling inhibitors in bone regeneration or disease models can provide insights into the therapeutic potential and safety of the inhibitors and activators.

In clinical trials, a combination of delivery systems including stem cells, growth factors, and biomaterials could provide optimized BMP-2 therapy to address the dual challenge of maintaining BMP-2 activity while achieving targeted delivery. Minimizing dosing requires understanding the individual patient’s perception of BMP-2 and tailoring treatment to individual needs. Controlled release is essential to stimulate the endogenous healing cascade. Existing knowledge must be combined and passed through the approval process to optimize the use of BMP-2 in BTE.

Conclusion

Globally, BMP-2 has shown great potential in bone regeneration, but the side effects caused by overdosage and short half-life have limited its application. This review analyzes historical aspects and clinical issues, and cutting-edge findings on BMP-2 efficacy and functions. The synergistic effects of BMP-2 with various biomaterials, growth factors, and molecular engineering may provide strategies for future bone regeneration and repair. In conclusion, continuing basic research is needed to elucidate the details of its function and the underlying signaling pathways involved to ensure the efficacy and safety of BMP-2 in clinical use.

Not applicable.

Author Contributions: J.Q. contributed to writing—original draft preparation; G.L. and H.W. contributed to review and editing. All authors have read and agreed to the published version of the manuscript.

Availability of Data and Material: Not applicable.

Ethical Approval: This study was approved by our institutional review board.

Statement of Human and Animal Rights: This article does not contain any studies with human or animal subjects.

Statement of Informed Consent: There are no human subjects in this article and informed consent is not applicable.

Consent for Publication: Not applicable.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: This work is supported by The Nature Science Foundation of Hunan Province, China (No.2023JJ30829).

ORCID iD: Gengyan Liu https://orcid.org/0009-0000-5261-1952
==== Refs
References

1. Halloran D Durbano HW Nohe A . Bone morphogenetic protein-2 in development and bone homeostasis. J Dev Biol. 2020;8 (3 ). doi:10.3390/jdb8030019.
2. Dai J Li L Jiang C Wang C Chen H Chai Y . Bone morphogenetic protein for the healing of tibial fracture: a meta-analysis of randomized controlled trials. PLoS One. 2015;10 (10 ):e0141670. doi:10.1371/journal.pone.0141670.
3. Haubruck P Tanner MC Vlachopoulos W Hagelskamp S Miska M Ober J Fischer C Schmidmaier G . Comparison of the clinical effectiveness of bone morphogenic protein (BMP)-2 and -7 in the adjunct treatment of lower limb nonunions. Orthop Traumatol Surg Res. 2018;104 (8 ):1241–48. doi:10.1016/j.otsr.2018.08.008.
4. Xu C Wang M Zandieh-Doulabi B Sun W Wei L Liu Y . To B (bone morphogenic protein-2) or not to B (bone morphogenic protein-2): Mesenchymal stem cells may explain the protein’s role in osteosarcomagenesis. Front Cell Dev Biol. 2021;9 :740783. doi:10.3389/fcell.2021.740783.34869325
5. Lowery JW Rosen V . The BMP pathway and its inhibitors in the skeleton. Physiol Rev. 2018;98 (4 ):2431–52. doi:10.1152/physrev.00028.2017.
6. Jeong CH Lim SY Um JE Lim HW Hwang KH Park KM Yun JS Kim D Huh JK Kim HS Yook JI , et al . Micellized protein transduction domain-bone morphogenetic protein-2 accelerates bone healing in a rat tibial distraction osteogenesis model. Acta Biomater. 2023;170 :360–75. doi:10.1016/j.actbio.2023.08.031.
7. Huang H Wismeijer D Hunziker EB Wu G . The acute inflammatory response to absorbed collagen sponge is not enhanced by BMP-2. Int J Mol Sci. 2017;18 (3 ):498. doi:10.3390/ijms18030498.28245606
8. Bordukalo-Nikšić T Kufner V Vukičević S . The role of BMPs in the regulation of osteoclasts resorption and bone remodeling: from experimental models to clinical applications. Front Immunol. 2022;13 :869422. doi:10.3389/fimmu.2022.869422.35558080
9. Herford AS . The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillofacial trauma. Chin J Traumatol. 2017;20 (1 ):1–3. doi:10.1016/js.cjtee.2016.05.004.28236566
10. Abel F Tan ET Sneag DB Lebl DR Chazen JL . Postoperative lumbar fusion bone morphogenic protein-related epidural cyst formation. AJNR Am J Neuroradiol. 2023;44 (3 ):351–55. doi:10.3174/ajnr.A7799.
11. Carragee EJ Chu G Rohatgi R Hurwitz EL Weiner BK Yoon ST Comer G Kopjar B . Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am. 2013;95 (17 ):1537–45. doi:10.2106/jbjs.L.01483.
12. Kukreja S Ahmed OI Haydel J Nanda A Sin AH . Complications of anterior cervical fusion using a low-dose recombinant human bone morphogenetic protein-2. Korean J Spine. 2015;12 (2 ):68–74. doi:10.14245/kjs.2015.12.2.68.26217385
13. Zhu L Liu Y Wang A Zhu Z Li Y Zhu C Che Z Liu T Liu H Huang L . Application of BMP in bone tissue engineering. Front Bioeng Biotechnol. 2022;10 :810880. doi:10.3389/fbioe.2022.810880.35433652
14. Roseti L Parisi V Petretta M Cavallo C Desando G Bartolotti I Grigolo B . Scaffolds for bone tissue engineering: State of the art and new perspectives. Mater Sci Eng C Mater Biol Appl. 2017;78 :1246–62. doi:10.1016/j.msec.2017.05.017.
15. Lu DC Tumialán LM Chou D . Multilevel anterior cervical discectomy and fusion with and without rhBMP-2: a comparison of dysphagia rates and outcomes in 150 patients. J Neurosurg Spine. 2013;18 (1 ):43–49. doi:10.3171/2012.10.Spine10231.23157278
16. Dec P Modrzejewski A Pawlik A . Existing and novel biomaterials for bone tissue engineering. Int J Mol Sci. 2022;24 (1 ):529. doi:10.3390/ijms24010529.36613972
17. Schemitsch EH . Size matters: defining critical in bone defect size! J Orthop Trauma. 2017;31 (Suppl 5 ):S20–22. doi:10.1097/bot.0000000000000978.
18. Migliorini F La Padula G Torsiello E Spiezia F Oliva F Maffulli N . Strategies for large bone defect reconstruction after trauma, infections or tumour excision: a comprehensive review of the literature. Eur J Med Res. 2021;26 (1 ):118. doi:10.1186/s40001-021-00593-9.34600573
19. Chang X Xu S Zhang H . Regulation of bone health through physical exercise: mechanisms and types. Front Endocrinol. 2022;13 :1029475. doi:10.3389/fendo.2022.1029475.
20. Fu R Liu C Yan Y Li Q Huang RL . Bone defect reconstruction via endochondral ossification: a developmental engineering strategy. J Tissue Eng. 2021;12 :20417314211004211. doi:10.1177/20417314211004211.33868628
21. Jiang S Wang M He J . A review of biomimetic scaffolds for bone regeneration: toward a cell-free strategy. Bioeng Transl Med. 2021;6 (2 ):e10206. doi:10.1002/btm2.102006.
22. Oliveira ÉR Nie L Podstawczyk D Allahbakhsh A Ratnayake J Brasil DL Shavandi A . Advances in growth factor delivery for bone tissue engineering. Int J Mol Sci. 2021;22 (2 ):903.33477502
23. Godoy-Gallardo M Portolés-Gil N López-Periago AM Domingo C Hosta-Rigau L . Multi-layered polydopamine coatings for the immobilization of growth factors onto highly-interconnected and bimodal PCL/HA-based scaffolds. Mater Sci Eng C Mater Biol Appl. 2020;117 :111245. doi:10.1016/j.msec.2020.111245.32919623
24. Di Luca A Klein-Gunnewiek M Vancso JG van Blitterswijk CA Benetti EM Moroni L . Covalent binding of bone morphogenetic protein-2 and transforming growth factor-β3 to 3D plotted scaffolds for osteochondral tissue regeneration. Biotechnol J. 2017;12 (12 ):10.1002/biot.201700072. doi:10.1002/biot.201700072.
25. Lienemann PS Lutolf MP Ehrbar M . Biomimetic hydrogels for controlled biomolecule delivery to augment bone regeneration. Adv Drug Deliv Rev. 2012;64 (12 ):1078–89. doi:10.1016/j.addr.2012.03.010.
26. King WJ Krebsbach PH . Growth factor delivery: how surface interactions modulate release in vitro and in vivo. Adv Drug Deliv Rev. 2012;64 (12 ):1239–56. doi:10.1016/j.addr.2012.03.004.
27. Lo KW Ulery BD Ashe KM Laurencin CT . Studies of bone morphogenetic protein-based surgical repair. Adv Drug Deliv Rev. 2012;64 (12 ):1277–91. doi:10.1016/j.addr.2012.03.014.
28. Hu C Li L . Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med. 2018;22 (3 ):1428–42. doi:10.1111/jcmm.13492.
29. Murphy SV Atala A . 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32 (8 ):773–85. doi:10.1038/nbt.2958.
30. Guan X Avci-Adali M Alarçin E Cheng H Kashaf SS Li Y Chawla A Jang HL Khademhosseini A . Development of hydrogels for regenerative engineering. Biotechnol J. 2017;12 (5 ):10.1002/biot.201600394. doi:10.1002/biot.201600394.
31. Burdick JA Prestwich GD . Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23 (12 ):H41–56. doi:10.1002/adma.201003963.
32. Andersen T Auk-Emblem P Dornish M . 3D cell culture in alginate hydrogels. Microarrays. 2015;4 (2 ):133–61. doi:10.3390/microarrays4020133.
33. Choe G Lee M Oh S Seok JM Kim J Im S Park SA Lee JY . Three-dimensional bioprinting of mesenchymal stem cells using an osteoinductive bioink containing alginate and BMP-2-loaded PLGA nanoparticles for bone tissue engineering. Biomater Adv. 2022;136 :212789. doi:10.1016/j.bioadv.2022.212789.35929321
34. Lin H Tang Y Lozito TP Oyster N Wang B Tuan RS . Efficient in vivo bone formation by BMP-2 engineered human mesenchymal stem cells encapsulated in a projection stereolithographically fabricated hydrogel scaffold. Stem Cell Res Ther. 2019;10 (1 ):254. doi:10.1186/s13287-019-1350-6.
35. Mahendiran B Muthusamy S Janani G Mandal BB Rajendran S Krishnakumar GS . Surface modification of decellularized natural cellulose scaffolds with organosilanes for bone tissue regeneration. ACS Biomater Sci Eng. 2022;8 (5 ):2000–15. doi:10.1021/acsbiomaterials.1c01502.
36. Arias-Betancur A Badilla-Wenzel N Astete-Sanhueza Á Farfán-Beltrán N Dias FJ . Carrier systems for bone morphogenetic proteins: an overview of biomaterials used for dentoalveolar and maxillofacial bone regeneration. Jpn Dent Sci Rev. 2022;58 :316–27. doi:10.1016/j.jdsr.2022.10.001.
37. Hettiaratchi MH Miller T Temenoff JS Guldberg RE McDevitt TC . Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2. Biomaterials. 2014;35 (25 ):7228–38. doi:10.1016/j.biomaterials.2014.05.011.
38. Wang J Xiao L Wang W Zhang D Ma Y Zhang Y Wang X . The auxiliary role of heparin in bone regeneration and its application in bone substitute materials. Front Bioeng Biotechnol. 2022;10 :837172. doi:10.3389/fbioe.2022.837172.35646879
39. Wu M Wu S Chen W Li YP . The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell Res. 2024;34 (2 ):101–23. doi:10.1038/s41422-023-00918-9.
40. Yang HS La WG Cho YM Shin W Yeo GD Kim BS . Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration. Exp Mol Med. 2012;44 (5 ):350–55. doi:10.3858/emm.2012.44.5.039.
41. Johnson MR Boerckel JD Dupont KM Guldberg RE . Functional restoration of critically sized segmental defects with bone morphogenetic protein-2 and heparin treatment. Clin Orthop Relat Res. 2011;469 (11 ):3111–17. doi:10.1007/s11999-011-2012-x.
42. Jeon O Powell C Solorio LD Krebs MD Alsberg E . Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. J Control Release. 2011;154 (3 ):258–66. doi:10.1016/j.jconrel.2011.06.027.
43. Casanova EA Rodriguez-Palomo A Stähli L Arnke K Gröninger O Generali M Neldner Y Tiziani S Dominguez AP Guizar-Sicairos M Gao Z , et al . SAXS imaging reveals optimized osseointegration properties of bioengineered oriented 3D-PLGA/aCaP scaffolds in a critical size bone defect model. Biomaterials. 2023;294 :121989. doi:10.1016/j.biomaterials.2022.121989.36628888
44. Onodera Y Kobayashi J Mitani S Hosoda C Banno K Horie K Okano T Shimizu T Shima M Tatsumi K . Terminus-selective covalent immobilization of heparin on a thermoresponsive surface using click chemistry for efficient binding of basic fibroblast growth factor. Macromol Biosci. 2024;24 (2 ):e2300307. doi:10.1002/mabi.202300307.
45. Hettiaratchi MH Krishnan L Rouse T Chou C McDevitt TC Guldberg RE . Heparin-mediated delivery of bone morphogenetic protein-2 improves spatial localization of bone regeneration. Sci Adv. 2020;6 (1 ):eaay1240. doi:10.1126/sciadv.aay1240.
46. Kostenko A Swioklo S Connon CJ . Alginate in corneal tissue engineering. Biomed Mater. 2022;17 (2 ):10.1088/1748-605X/ac4d7b. doi:10.1088/1748-605X/ac4d7b.
47. Lee YH Lee BW Jung YC Yoon BI Woo HM Kang BJ . Application of alginate microbeads as a carrier of bone morphogenetic protein-2 for bone regeneration. J Biomed Mater Res B Appl Biomater. 2019;107 (2 ):286–94. doi:10.1002/jbm.b.34119.
48. Kolambkar YM Dupont KM Boerckel JD Huebsch N Mooney DJ Hutmacher DW Guldberg RE . An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials. 2011;32 (1 ):65–74. doi:10.1016/j.biomaterials.2010.08.074.20864165
49. Priddy LB Chaudhuri O Stevens HY Krishnan L Uhrig BA Willett NJ Guldberg RE . Oxidized alginate hydrogels for bone morphogenetic protein-2 delivery in long bone defects. Acta Biomater. 2014;10 (10 ):4390–99. doi:10.1016/j.actbio.2014.06.015.
50. Mumcuoglu D Fahmy-Garcia S Ridwan Y Nicke J Farrell E Kluijtmans SG van Osch GJ . Injectable BMP-2 delivery system based on collagen-derived microspheres and alginate induced bone formation in a time- and dose-dependent manner. Eur Cells Mater. 2018;35 :242–54. doi:10.22203/eCM.v035a17.
51. Bayer EA Jordan J Roy A Gottardi R Fedorchak MV Kumta PN Little SR . Programmed Platelet-derived growth factor-BB and bone morphogenetic protein-2 delivery from a hybrid calcium phosphate/alginate scaffold. Tissue Eng Part A. 2017;23 (23–24 ):1382–93. doi:10.1089/ten.TEA.2017.0027.
52. Khatami N Khoshfetrat AB Khaksar MR Zamani ARN Rahbarghazi R . Collagen-alginate-nano-silica microspheres improved the osteogenic potential of human osteoblast-like MG-63 cells. J Cell Biochem. 2019;120 (9 ):15069–82. doi:10.1002/jcb.28768.
53. Maji K Dasgupta S Bhaskar R Gupta MK . Photo-crosslinked alginate nano-hydroxyapatite paste for bone tissue engineering. Biomed Mater. 2020;15 (5 ):055019. doi:10.1088/1748-605X/ab9551.32438363
54. Freeman FE Pitacco P van Dommelen LHA Nulty J Browe DC Shin JY Alsberg E Kelly DJ . 3D bioprinting spatiotemporally defined patterns of growth factors to tightly control tissue regeneration. Sci Adv. 2020;6 (33 ):eabb5093. doi:10.1126/sciadv.abb5093.
55. Krishnan L Priddy LB Esancy C Klosterhoff BS Stevens HY Tran L Guldberg RE . Delivery vehicle effects on bone regeneration and heterotopic ossification induced by high dose BMP-2. Acta Biomater. 2017;49 :101–12. doi:10.1016/j.actbio.2016.12.012.
56. Liu W Madry H Cucchiarini M . Application of alginate hydrogels for next-generation articular cartilage regeneration. Int J Mol Sci. 2022;23 (3 ):1147. doi:10.3390/ijms23031147.35163071
57. Arlov Ø Aachmann FL Sundan A Espevik T Skjåk-Bræk G . Heparin-like properties of sulfated alginates with defined sequences and sulfation degrees. Biomacromolecules. 2014;15 (7 ):2744–50. doi:10.1021/bm500602w.
58. Mhanna R Kashyap A Palazzolo G Vallmajo-Martin Q Becher J Möller S Schnabelrauch M Zenobi-Wong M . Chondrocyte culture in three dimensional alginate sulfate hydrogels promotes proliferation while maintaining expression of chondrogenic markers. Tissue Eng Part A. 2014;20 (9–10 ):1454–64. doi:10.1089/ten.TEA.2013.0544.
59. Tang G Tan Z Zeng W Wang X Shi C Liu Y He H Chen R Ye X . Recent advances of chitosan-based injectable hydrogels for bone and dental tissue regeneration. Front Bioeng Biotechnol. 2020;8 :587658. doi:10.3389/fbioe.2020.587658.33042982
60. Kyzas GZ Bikiaris DN . Recent modifications of chitosan for adsorption applications: a critical and systematic review. Mar Drugs. 2015;13 (1 ):312–37. doi:10.3390/md13010312.
61. Yoon SJ Yoo Y Nam SE Hyun H Lee DW Um S Kim SY Hong SO Yang DH Chun HJ . The cocktail effect of BMP-2 and TGF-β1 loaded in visible light-cured glycol chitosan hydrogels for the enhancement of bone formation in a rat tibial defect model. Mar Drugs. 2018;16 (10 ):351. doi:10.3390/md16100351.30257482
62. Shu Y Yu Y Zhang S Wang J Xiao Y Liu C . The immunomodulatory role of sulfated chitosan in BMP-2-mediated bone regeneration. Biomater Sci. 2018;6 (9 ):2496–2507. doi:10.1039/c8bm00701b.30091436
63. Qi J Yu T Hu B Wu H Ouyang H . Current biomaterial-based bone tissue engineering and translational medicine. Int J Mol Sci. 2021;22 (19 ):10233. doi:10.3390/ijms221910233.34638571
64. Gentile P Chiono V Carmagnola I Hatton PV . An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15 (3 ):3640–59. doi:10.3390/ijms15033640.
65. Bouyer M Guillot R Lavaud J Plettinx C Olivier C Curry V Boutonnat J Coll JL Peyrin F Josserand V Bettega G , et al . Surface delivery of tunable doses of BMP-2 from an adaptable polymeric scaffold induces volumetric bone regeneration. Biomaterials. 2016;104 :168–81. doi:10.1016/j.biomaterials.2016.06.001.
66. Minardi S Fernandez-Moure JS Fan D Murphy MB Yazdi IK Liu X Weiner BK Tasciotti E . Biocompatible PLGA-mesoporous silicon microspheres for the controlled release of BMP-2 for bone augmentation. Pharmaceutics. 2020;12 (2 ):118. doi:10.3390/pharmaceutics12020118.32024134
67. Hsu YH Lin CT Yu YH Chou YC Liu SJ Chan EC . Dual delivery of active antibactericidal agents and bone morphogenetic protein at sustainable high concentrations using biodegradable sheath-core-structured drug-eluting nanofibers. Int J Nanomedicine. 2016;11 :3927–37. doi:10.2147/ijn.S107250.
68. Szcześ A Hołysz L Chibowski E . Synthesis of hydroxyapatite for biomedical applications. Adv Colloid Interface Sci. 2017;249 :321–30. doi:10.1016/j.cis.2017.04.007.
69. Dutta SR Passi D Singh P Bhuibhar A . Ceramic and non-ceramic hydroxyapatite as a bone graft material: a brief review. Ir J Med Sci. 2015;184 (1 ):101–6. doi:10.1007/s11845-014-1199-8.
70. Xiong L Zeng J Yao A Tu Q Li J Yan L Tang Z . BMP2-loaded hollow hydroxyapatite microspheres exhibit enhanced osteoinduction and osteogenicity in large bone defects. Int J Nanomedicine. 2015;10 :517–26. doi:10.2147/ijn.S74677.
71. El-Rashidy AA Roether JA Harhaus L Kneser U Boccaccini AR . Regenerating bone with bioactive glass scaffolds: a review of in Vivo studies in bone defect models. Acta Biomater. 2017;62 :1–28. doi:10.1016/j.actbio.2017.08.030.28844964
72. Mouriño V Cattalini JP Roether JA Dubey P Roy I Boccaccini AR . Composite polymer-bioceramic scaffolds with drug delivery capability for bone tissue engineering. Expert Opin Drug Deliv. 2013;10 (10 ):1353–65. doi:10.1517/17425247.2013.808183.
73. Xin T Mao J Liu L Tang J Wu L Yu X Gu Y Cui W Chen L . Programmed Sustained release of recombinant human bone morphogenetic protein-2 and inorganic ion composite hydrogel as artificial periosteum. ACS Appl Mater Interfaces. 2020;12 (6 ):6840–51. doi:10.1021/acsami.9b18496.
74. Lin D Chai Y Ma Y Duan B Yuan Y Liu C . Rapid initiation of guided bone regeneration driven by spatiotemporal delivery of IL-8 and BMP-2 from hierarchical MBG-based scaffold. Biomaterials. 2019;196 :122–37. doi:10.1016/j.biomaterials.2017.11.011.
75. Berkmann JC Herrera Martin AX Pontremoli C Zheng K Bucher CH Ellinghaus A Boccaccini AR Fiorilli S Vitale Brovarone C Duda GN Schmidt-Bleek K . In vivo validation of spray-dried mesoporous bioactive glass microspheres acting as prolonged local release systems for BMP-2 to support bone regeneration. Pharmaceutics. 2020;12 (9 ):823. doi:10.3390/pharmaceutics12090823.32872353
76. Gong X Zhang Q Gao Y Shuang S Choi MM Dong C . Phosphorus and nitrogen dual-doped hollow carbon dot as a nanocarrier for doxorubicin delivery and biological imaging. ACS Appl Mater Interfaces. 2016;8 (18 ):11288–97. doi:10.1021/acsami.6b01577.
77. Rajabnejadkeleshteri A Basiri H Mohseni SS Farokhi M Mehrizi AA Moztarzadeh F . Preparation of microfluidic-based pectin microparticles loaded carbon dots conjugated with BMP-2 embedded in gelatin-elastin-hyaluronic acid hydrogel scaffold for bone tissue engineering application. Int J Biol Macromol. 2021;184 :29–41. doi:10.1016/j.ijbiomac.2021.05.148.34048836
78. Yang L Wang Z Wang J Jiang W Jiang X Bai Z He Y Jiang J Wang D Yang L . Doxorubicin conjugated functionalizable carbon dots for nucleus targeted delivery and enhanced therapeutic efficacy. Nanoscale. 2016;8 (12 ):6801–6809. doi:10.1039/c6nr00247a.26957191
79. Zhang J Zheng M Xie Z . Co-assembled hybrids of proteins and carbon dots for intracellular protein delivery. J Mater Chem B. 2016;4 (34 ):5659–63. doi:10.1039/c6tb01622g.
80. Whitty C Pernstich C Marris C McCaskie A Jones M Henson F . Sustained delivery of the bone morphogenetic proteins BMP-2 and BMP-7 for cartilage repair and regeneration in osteoarthritis. Osteoarthr Cartil Open. 2022;4 (1 ):100240. doi:10.1016/j.ocarto.2022.100240.36474464
81. Karaman S Leppänen VM Alitalo K . Vascular endothelial growth factor signaling in development and disease. Development. 2018;145 (14 ):dev151019. doi:10.1242/dev.151019.
82. Liu Y Berendsen AD Jia S Lotinun S Baron R Ferrara N Olsen BR . Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest. 2012;122 (9 ):3101–13. doi:10.1172/jci61209.
83. Olsen JJ Pohl S Deshmukh A Visweswaran M Ward NC Arfuso F Agostino M Dharmarajan A . The role of Wnt signalling in angiogenesis. Clin Biochem Rev. 2017;38 (3 ):131–42.
84. Liu K Meng CX Lv ZY Zhang YJ Li J Li KY Liu FZ Zhang B Cui FZ . Enhancement of BMP-2 and VEGF carried by mineralized collagen for mandibular bone regeneration. Regen Biomater. 2020;7 (4 ):435–40. doi:10.1093/rb/Rbaa022.
85. Wang T Guo S Zhang H . Synergistic effects of controlled-released BMP-2 and VEGF from nHAC/PLGAs scaffold on osteogenesis. Biomed Res Int. 2018;2018 :3516463. doi:10.1155/2018/3516463.30345299
86. Wang H Zou Q Boerman OC Nijhuis AW Jansen JA Li Y Leeuwenburgh SC . Combined delivery of BMP-2 and bFGF from nanostructured colloidal gelatin gels and its effect on bone regeneration in vivo. J Control Release. 2013;166 (2 ):172–81. doi:10.1016/j.jconrel.2012.12.015.
87. Wu C Han P Liu X Xu M Tian T Chang J Xiao Y . Mussel-inspired bioceramics with self-assembled Ca-P/polydopamine composite nanolayer: preparation, formation mechanism, improved cellular bioactivity and osteogenic differentiation of bone marrow stromal cells. Acta Biomater. 2014;10 (1 ):428–38. doi:10.1016/j.actbio.2013.10.013.
88. Sun H Dong J Wang Y Shen S Shi Y Zhang L Zhao J Sun X Jiang Q . Polydopamine-Coated Poly(l-lactide) nanofibers with controlled release of VEGF and BMP-2 as a regenerative periosteum. ACS Biomater Sci Eng. 2021;7 (10 ):4883–97. doi:10.1021/acsbiomaterials.1c00246.
89. Geng Y Duan H Xu L Witman N Yan B Yu Z Wang H Tan Y Lin L Li D , et al . BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways. Commun Biol. 2021;4 (1 ):82. doi:10.1038/s42003-020-01606-9.33469143
90. Yu Z Witman N Wang W Li D Yan B Deng M Wang X Wang H Zhou G Liu W Sahara M , et al . Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. J Control Release. 2019;310 :103–14. doi:10.1016/j.jconrel.2019.08.014.
91. Balmayor ER Geiger JP Aneja MK Berezhanskyy T Utzinger M Mykhaylyk O Rudolph C Plank C . Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats. Biomaterials. 2016;87 :131–46. doi:10.1016/j.biomaterials.2016.02.018.
92. Khorsand B Elangovan S Hong L Dewerth A Kormann MS Salem AK . A Comparative study of the bone regenerative effect of chemically modified RNA encoding BMP-2 or BMP-9. AAPS J. 2017;19 (2 ):438–46. doi:10.1208/s12248-016-0034-8.
93. Seo I Kim SW Hyun J Kim YJ Park HS Yoon JK Bhang SH . Enhancing viability and angiogenic efficacy of mesenchymal stem cells via HSP90α and HSP27 regulation based on ROS stimulation for wound healing. Bioeng Transl Med. 2023;8 (5 ):e10560. doi:10.1002/btm2.10560.
94. Qi W Yan J Sun H Wang H . Multifunctional nanocomposite films for synergistic delivery of bFGF and BMP-2. ACS Omega. 2017;2 (3 ):899–909. doi:10.1021/acsomega.6b00420.30023619
95. Luong LN Ramaswamy J Kohn DH . Effects of osteogenic growth factors on bone marrow stromal cell differentiation in a mineral-based delivery system. Biomaterials. 2012;33 (1 ):283–94. doi:10.1016/j.biomaterials.2011.09.052.
96. Jann J Gascon S Roux S Faucheux N . Influence of the TGF-β superfamily on osteoclasts/osteoblasts balance in physiological and pathological bone conditions. Int J Mol Sci. 2020;21 (20 ). doi:10.3390/ijms21207597.
97. James AW Pan A Chiang M Zara JN Zhang X Ting K Soo C . A new function of Nell-1 protein in repressing adipogenic differentiation. Biochem Biophys Res Commun. 2011;411 (1 ):126–31. doi:10.1016/j.bbrc.2011.06.111.
98. Cowan CM Zhang X James AW Kim TM Sun N Wu B Ting K Soo C . NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2. Biochem Biophys Res Commun. 2012;422 (3 ):351–57. doi:10.1016/j.bbrc.2012.04.077.
99. Pakvasa M Alverdy A Mostafa S Wang E Fu L Li A Oliveira L Athiviraham A Lee MJ Wolf JM He TC , et al . Neural EGF-like protein 1 (NELL-1): Signaling crosstalk in mesenchymal stem cells and applications in regenerative medicine. Genes Dis. 2017;4 (3 ):127–37. doi:10.1016/j.gendis.2017.07.006.
100. Kraja AT Borecki IB Tsai MY Ordovas JM Hopkins PN Lai CQ Frazier-Wood AC Straka RJ Hixson JE Province MA Arnett DK . Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study. Lipids. 2013;48 (2 ):155–65. doi:10.1007/s11745-012-3740-8.
101. Li C Zhang X Zheng Z Nguyen A Ting K Soo C . Nell-1 is a key functional modulator in osteochondrogenesis and beyond. J Dent Res. 2019;98 (13 ):1458–68. doi:10.1177/0022034519882000.
102. Fahmy-Garcia S van Driel M Witte-Buoma J , et al . NELL-1, HMGB1, and CCN2 enhance migration and vasculogenesis, but not osteogenic differentiation compared to BMP2. Tissue Eng Part A. 2018;24 (3–4 ):207–18. doi:10.1089/ten.TEA.2016.0537.
103. Liu L Lam WM Naidu M Yang Z Wang M Ren X Hu T Kumarsing R Ting K Goh JC Wong HK . Synergistic effect of NELL-1 and an ultra-low dose of BMP-2 on spinal fusion. Tissue Eng Part A. 2019;25 (23–24 ):1677–89. doi:10.1089/ten.TEA.2019.0124.
104. Shen J James AW Zhang X Pang S Zara JN Asatrian G Chiang M Lee M Khadarian K Nguyen A Lee KS , et al . Novel Wnt regulator NEL-like molecule-1 antagonizes adipogenesis and augments osteogenesis induced by bone morphogenetic protein 2. Am J Pathol. 2016;186 (2 ):419–34. doi:10.1016/j.ajpath.2015.10.011.
105. Kwak JH Zhang Y Park J Chen E Shen J Chawan C Tanjaya J Lee S Zhang X Wu BM Ting K , et al . Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration. Biomaterials. 2015;57 :73–83. doi:10.1016/j.biomaterials.2015.03.063.25913252
106. Yang X Mou D Yu Q Zhang J Xiong Y Zhang Z Xing S . Nerve growth factor promotes osteogenic differentiation of MC3T3-E1 cells via BMP-2/Smads pathway. Ann Anat. 2022;239 :151819. doi:10.1016/j.aanat.2021.151819.34391912
107. Rivera KO Russo F Boileau RM Tomlinson RE Miclau T Marcucio RS Desai TA Bahney CS . Local injections of β-NGF accelerate endochondral fracture repair by promoting cartilage to bone conversion. Sci Rep. 2020;10 (1 ):22241. doi:10.1038/s41598-020-78983-y.33335129
108. Yang S Cheng J Man C Jiang L Long G Zhao W Zheng D . Effects of exogenous nerve growth factor on the expression of BMP-9 and VEGF in the healing of rabbit mandible fracture with local nerve injury. J Orthop Surg Res. 2021;16 (1 ):74. doi:10.1186/s13018-021-02220-z.33478541
109. Zhao L Lai Y Jiao H Huang J . Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints. Nat Commun. 2024;15 (1 ):3225. doi:10.1038/s41467-024-47633-6.38622181
110. Planchestainer M Roura Padrosa D Contente ML Paradisi F . Genetically fused T4L acts as a shield in covalent enzyme immobilisation enhancing the rescued activity. Catalysts. 2018;8 (1 ):40.
111. Thorsen TS Matt R Weis WI Kobilka BK . Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis. Structure. 2014;22 (11 ):1657–64. doi:10.1016/j.str.2014.08.022.
112. Chen XY Tan B Bao Z Wang S Tang R Wang Z Chen G Chen S Lu WW Yang D Peng S . Enhanced bone regeneration via spatiotemporal and controlled delivery of a genetically engineered BMP-2 in a composite hydrogel. Biomaterials. 2021;277 :121117. doi:10.1016/j.biomaterials.2021.121117.34517277
113. Motyl KJ Guntur AR Carvalho AL Rosen CJ . Energy metabolism of bone. Toxicol Pathol. 2017;45 (7 ):887–93. doi:10.1177/0192623317737065.
114. Zhang J Tang L Qi H Zhao Q Liu Y Zhang Y . Dual function of magnesium in bone biomineralization. Adv Healthc Mater. 2019;8 (21 ):e1901030. doi:10.1002/adhm.201901030.
115. Lai LTF Balaraman J Zhou F Matthies D . Cryo-EM structures of human magnesium channel MRS2 reveal gating and regulatory mechanisms. Nat Commun. 2023;14 (1 ):7207. doi:10.1038/s41467-023-42599-3.37938562
116. Sakaguchi M Sharmin S Taguchi A Ohmori T Fujimura S Abe T Kiyonari H Komatsu Y Mishina Y Asashima M Araki E , et al . The phosphatase Dullard negatively regulates BMP signalling and is essential for nephron maintenance after birth. Nat Commun. 2013;4 :1398. doi:10.1038/ncomms2408.23360989
117. Wang J Xue Y Wang Y Liu C Hu S Zhao H Gu Q Yang H Huang L Zhou X Shi Q . BMP-2 functional polypeptides relieve osteolysis via bi-regulating bone formation and resorption coupled with macrophage polarization. NPJ Regen Med. 2023;8 (1 ):6. doi:10.1038/s41536-023-00279-2.36759627
118. Truchan K Osyczka AM . Noggin promotes osteogenesis in human adipose-derived mesenchymal stem cells via FGFR2/Src/Akt and ERK signaling pathway. Sci Rep. 2024;14 (1 ):6724. doi:10.1038/s41598-024-56858-w.38509118
119. Hsu MN Yu FJ Chang YH Huang KL Pham NN Truong VA Lin MW Kieu Nguyen NT Hwang SM Hu YC . CRISPR interference-mediated noggin knockdown promotes BMP2-induced osteogenesis and calvarial bone healing. Biomaterials. 2020;252 :120094. doi:10.1016/j.biomaterials.2020.120094.32422495
120. Airenne KJ Hu YC Kost TA Smith RH Kotin RM Ono C Matsuura Y Wang S Ylä-Herttuala S . Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther. 2013;21 (4 ):739–49. doi:10.1038/mt.2012.286.
121. Chen CY Wu HH Chen CP Chern SR Hwang SM Huang SF Lo WH Chen GY Hu YC . Biosafety assessment of human mesenchymal stem cells engineered by hybrid baculovirus vectors. Mol Pharm. 2011;8 (5 ):1505–14. doi:10.1021/mp100368d.
122. Lin CY Chang YH Kao CY Lu CH Sung LY Yen TC Lin KJ Hu YC . Augmented healing of critical-size calvarial defects by baculovirus-engineered MSCs that persistently express growth factors. Biomaterials. 2012;33 (14 ):3682–92. doi:10.1016/j.biomaterials.2012.02.007.
123. Sung LY Chen CL Lin SY Li KC Yeh CL Chen GY Lin CY Hu YC . Efficient gene delivery into cell lines and stem cells using baculovirus. Nat Protoc. 2014;9 (8 ):1882–99. doi:10.1038/nprot.2014.130.
124. Sung LY Chen CL Lin SY Hwang SM Lu CH Li KC Lan AS Hu YC . Enhanced and prolonged baculovirus-mediated expression by incorporating recombinase system and in cis elements: a comparative study. Nucleic Acids Res. 2013;41 (14 ):e139. doi:10.1093/nar/gkt442.
125. Biswas S Li P Wu H Shafiquzzaman M Murakami S Schneider MD Mishina Y Li B Li J . BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells. Sci Rep. 2018;8 (1 ):8475. doi:10.1038/s41598-018-26820-8.29855498
126. Vrathasha V Weidner H Nohe A . Mechanism of CK2.3, a novel mimetic peptide of bone morphogenetic protein receptor type IA, mediated osteogenesis. Int J Mol Sci. 2019;20 (10 ). doi:10.3390/ijms20102500.
127. Moseychuk O Akkiraju H Dutta J D’Angelo A Bragdon B Duncan RL Nohe A . Inhibition of CK2 binding to BMPRIa induces C2C12 differentiation into osteoblasts and adipocytes. J Cell Commun Signal. 2013;7 (4 ):265–78. doi:10.1007/s12079-013-0199-1.
128. Carragee EJ Hurwitz EL Weiner BK . A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11 (6 ):471–91. doi:10.1016/j.spinee.2011.04.023.
129. Carragee EJ Mitsunaga KA Hurwitz EL Scuderi GJ . Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J. 2011;11 (6 ):511–16. doi:10.1016/j.spinee.2011.02.013.
130. Aro HT Govender S Patel AD Hernigou P Perera de Gregorio A Popescu GI Golden JD Christensen J Valentin A . Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am. 2011;93 (9 ):801–808. doi:10.2106/jbjs.I.01763.21454742
131. Prados B Del Toro R MacGrogan D Gómez-Apiñániz P Papoutsi T Muñoz-Cánoves P Méndez-Ferrer S de la Pompa JL . Heterotopic ossification in mice overexpressing Bmp2 in Tie2+ lineages. Cell Death Dis. 2021;12 (8 ):729. doi:10.1038/s41419-021-04003-0.34294700
132. Lad SP Bagley JH Karikari IO Babu R Ugiliweneza B Kong M Isaacs RE Bagley CA Gottfried ON Patil CG Boakye M . Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery. 2013;73 (3 ):440–49. doi:10.1227/neu.0000000000000018.
133. Gao H Chakraborty G Lee-Lim AP Mo Q Decker M Vonica A Shen R Brogi E Brivanlou AH Giancotti FG . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012;150 (4 ):764–79. doi:10.1016/j.cell.2012.06.035.
134. Owens P Pickup MW Novitskiy SV Chytil A Gorska AE Aakre ME West J Moses HL . Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci U S A. 2012;109 (8 ):2814–19. doi:10.1073/pnas.1101139108.
135. Lee D Wufuer M Kim I Choi TH Kim BJ Jung HG Jeon B Lee G Jeon OH Chang H Yoon DS . Sequential dual-drug delivery of BMP-2 and alendronate from hydroxyapatite-collagen scaffolds for enhanced bone regeneration. Sci Rep. 2021;11 (1 ):746. doi:10.1038/s41598-020-80608-3.33436904
